Literature DB >> 16147584

Using intrathecal colistin for multidrug resistant shunt infection.

H Sueke1, H Marsh, A Dhital.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16147584     DOI: 10.1080/02688690500080729

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


× No keyword cloud information.
  7 in total

1.  Expert synthesis of the literature to support critical care decision making.

Authors:  Rebecca N Jerome; Randolph A Miller
Journal:  J Med Libr Assoc       Date:  2006-10

2.  Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Chun-Hong Tan; Jian Li; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

Review 3.  Polymyxins revisited.

Authors:  David Landman; Claudiu Georgescu; Don Antonio Martin; John Quale
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

Review 4.  Intrathecal/intraventricular colistin in external ventricular device-related infections by multi-drug resistant Gram negative bacteria: case reports and review.

Authors:  O Bargiacchi; A Rossati; P Car; D Brustia; R Brondolo; F Rosa; P L Garavelli; F G De Rosa
Journal:  Infection       Date:  2014-04-12       Impact factor: 3.553

Review 5.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

Review 6.  Management of meningitis due to antibiotic-resistant Acinetobacter species.

Authors:  Baek-Nam Kim; Anton Y Peleg; Thomas P Lodise; Jeffrey Lipman; Jian Li; Roger Nation; David L Paterson
Journal:  Lancet Infect Dis       Date:  2009-04       Impact factor: 25.071

Review 7.  Treatment options for multidrug-resistant Acinetobacter species.

Authors:  Jacob Gilad; Yehuda Carmeli
Journal:  Drugs       Date:  2008       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.